250 results on '"Chaplin, Paul"'
Search Results
2. A single vaccination with non-replicating MVA at birth induces both immediate and long-term protective immune responses
3. Abstract LB223: Intratumoral administration of modified vaccinia Ankara expressing a tumor associated antigen and the costimulatory molecules IL-12 and 4-1BBL induces potent systemic long-term immune responses against murine tumors
4. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies
5. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects
6. LB1579. A single and a two-dose regimen of MVA-BN elicit similar memory responses to a boost vaccination two years after the initial regimen, indicating potential flexibility for a delayed second dose of MVA-BN in the ongoing monkeypox emergency
7. One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
8. Single and 2-dose vaccinations with MVA-BN® induce durable B cell memory responses in healthy volunteers that are comparable to older generation replicating smallpox vaccines
9. Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis
10. Phase II randomized, double-blinded comparison of a single high dose (5 × 108 TCID50) of modified vaccinia Ankara compared to a standard dose (1 × 108 TCID50) in healthy vaccinia-naïve individuals
11. Single and 2-dose vaccinations with modified vaccinia Ankara-Bavarian Nordic® induce durable B cell memory responses comparable to replicating smallpox vaccines.
12. A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection
13. A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques
14. Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects
15. A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection
16. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA
17. Recombinant MVA generating excess early double-stranded RNA transiently activates PKR and triggers enhanced innate immune responses: ID: 78
18. The structural assessment of caravan holiday homes
19. Murine CD8α+ DCs and human CD141+ DCs produce large amounts of IFN-λ in response to dsRNA or DNA viruses [Abstract]
20. UK collective proceedings in 2022 and beyond.
21. A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques.
22. Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory
23. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection
24. Clinical and immunologic responses to multiple doses of IMVAMUNE ® (Modified Vaccinia Ankara) followed by Dryvax ® challenge
25. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)
26. Genetic stability of recombinant MVA-BN
27. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine
28. Murine CD8α+ DCs and human CD141+ DCs produce large amounts of IFN-λ in response to dsRNA or DNA viruses: PS2-006
29. Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine
30. A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS
31. Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trial
32. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
33. LB11. A Single Dose of the MVA-BN Smallpox Vaccine Induces an Early Protective Antibody Response Similar to a Traditional Replicating Vaccine and Is Suitable for Emergency Scenarios
34. Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses.
35. The cloning of cattle interferon-A subtypes Isolated from the gut epithelium of rotavirus-infected calves
36. Abstract 1468: Synergistic cancer immunotherapy combination of MVA-CD40L with tumor targeting antibodies or checkpoint blockade to achieve strong antitumor immune responses against large, established tumors
37. Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine.
38. The immune response to a DNA vaccine can be modulated by co-delivery of cytokine genes using a DNA prime-protein boost strategy
39. Induction of lymphocyte recruitment in the absence of a detectable immune response
40. Abstract 727: A novel rMVA combination immunotherapy triggers potent innate and adaptive immune responses against established tumors
41. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
42. CD70 encoded by modified vaccinia virus Ankara enhances CD8 T-cell-dependent protective immunity in MHC class II-deficient mice
43. NLRC4 Inflammasome-Driven Immunogenicity of a Recombinant MVA Mucosal Vaccine Encoding Flagellin
44. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles
45. Case Study: Captain Robert Falcon Scott’s 1910-13 British Antarctic Expedition Hut at Cape Evans
46. Polar Heritage at Risk: The Antarctic
47. Polar Heritage - Rubbish Or Relics?
48. Logistic and Other Factors Constraining Conservation of Heritage Sites in Antarctica
49. A Survey of Modern British Co‐operatives
50. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.